Cargando…
Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer
The human epidermal growth factor receptor 2 (HER2) is overexpressed in 13–22% of breast cancers (BC). Approximately 60–70% of HER2+ BC co-express hormone receptors (HRs). HR/HER2 co-expression modulates response to both anti-HER2–directed and endocrine therapy due to “crosstalk” between the estroge...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232442/ https://www.ncbi.nlm.nih.gov/pubmed/37258523 http://dx.doi.org/10.1038/s41523-023-00533-2 |